Stock DANCAN DANCANN PHARMA A/S
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dancann Pharma A/S

Equities

DANCAN

DK0061410487

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
0.056 DKK -4.76% Intraday chart for Dancann Pharma A/S +86.67% +86.67%
Mar. 29 Dancann Pharma Plans Up to DKK19 Million Rights Issue MT
Feb. 28 DanCann Pharma Notes Cannabis Legalization in Germany as Shares Surge MT

Valuation

Fiscal Period: December 2020 2021 2022
Capitalization 1 66.75 175.2 37.06
Enterprise Value (EV) 1 45.61 167.5 26.31
P/E ratio -6.71 x -12.7 x -2.31 x
Yield - - -
Capitalization / Revenue -13.8 x 200 x 5.15 x
EV / Revenue -9.44 x 192 x 3.66 x
EV / EBITDA -7.9 x -12.3 x -1.85 x
EV / FCF -1,584,675 x -5,222,178 x -1,496,042 x
FCF Yield -0% -0% -0%
Price to Book 1.51 x 3.28 x 0.59 x
Nbr of stocks (in thousands) 20,731 26,551 65,015
Reference price 2 3.220 6.600 0.5700
Announcement Date 4/7/21 4/12/22 5/12/23
1DKK in Million2DKK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022
Net sales 1 -0.4218 -4.83 0.874 7.189
EBITDA 1 -0.6189 -5.776 -13.62 -14.19
EBIT 1 -0.6268 -5.87 -14.51 -16.42
Operating Margin 148.6% 121.55% -1,659.95% -228.38%
Earnings before Tax (EBT) 1 -0.6384 -5.986 -15.18 -18.25
Net income 1 -0.4998 -4.255 -11.75 -16.06
Net margin 118.5% 88.09% -1,344.39% -223.45%
EPS - -0.4801 -0.5200 -0.2471
Free Cash Flow - -28.78 -32.07 -17.58
FCF margin - 595.93% -3,669.89% -244.6%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 4/7/21 4/7/21 4/12/22 5/12/23
1DKK in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2023 Q1
Net sales 1 1.266 0.62
EBITDA - -
EBIT - -
Operating Margin - -
Earnings before Tax (EBT) - -
Net income - -
Net margin - -
EPS 2 -0.0100 -0.0500
Dividend per Share - -
Announcement Date 5/18/22 5/31/23
1DKK in Million2DKK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022
Net Debt 1 - - - -
Net Cash position 1 0.18 21.1 7.74 10.8
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - -28.8 -32.1 -17.6
ROE (net income / shareholders' equity) - -19.5% -24.1% -27.7%
ROA (Net income/ Total Assets) - -14.4% -15.3% -14.4%
Assets 1 - 29.58 76.81 111.7
Book Value Per Share - 2.140 2.010 0.9700
Cash Flow per Share - 1.030 0.2900 0.1700
Capex 1 0.06 4.02 6.37 1.01
Capex / Sales -14.62% -83.14% 728.83% 13.99%
Announcement Date 4/7/21 4/7/21 4/12/22 5/12/23
1DKK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
DANCANN PHARMA A/S Stock Dancann Pharma A/S
+86.67% 1.34M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. DANCAN Stock
  4. Financials Dancann Pharma A/S